Chinese hepatitis B drug market into "fat" opened the prelude to the battle for pharmaceutical compa

For the global pharmaceutical companies, China hepatitis B drug market is the most attractive “ fat ” one of the next ten years, Chinese will continue to be the largest market of hepatitis B, the size of the market is expected to grow from nearly $923 million in 2014 to more than $1 billion 400 million in 2024. In this regard, a fight against hepatitis B drug patent protection has begun to kick off.

China's chronic hepatitis B virus carriers account for about 34% of the world. According to research and consulting firm GlobalData data, the next ten years, China will continue to be the largest major hepatitis B market, the market is expected to grow from nearly $923 million in 2014 to more than $1 billion 400 million in 2024.

But these ten years, is also very likely to become the current hepatitis B drugs in China's last profitable gold for ten years. According to the National Planning Commission statistics, the implementation of the China vaccination based comprehensive prevention and control of hepatitis B virus strategy has achieved remarkable results, the reported incidence of hepatitis B was decreased year by year, and is expected to enter the state of low prevalence of hepatitis B after.

All kinds of environment staggered, multinational pharmaceutical companies, domestic generics enterprises pay more attention to it than at any time in the past ten years of market competition, therefore, a hepatitis B drug patent protection battle prelude.